Abstract
The mapping of SARS-CoV-2 human protein-protein interactions by Gordon and colleagues revealed druggable targets that are hijacked by the virus. Here, we highlight several oncogenic pathways identified at the host-virus interface of SARS-CoV-2 to enable cancer biologists to apply their knowledge for rapid drug repurposing to treat COVID-19, and help inform the response to potential long-term complications of the disease.
©2020 American Association for Cancer Research.
MeSH terms
-
Betacoronavirus*
-
COVID-19
-
Cell Cycle
-
Coronavirus Infections / drug therapy*
-
Coronavirus Infections / genetics
-
Coronavirus Infections / metabolism
-
Coronavirus Infections / physiopathology
-
DNA Damage
-
Drug Repositioning*
-
Epigenomics
-
Humans
-
Neoplasm Proteins / antagonists & inhibitors*
-
Neoplasm Proteins / drug effects
-
Neoplasms / drug therapy*
-
Neoplasms / genetics
-
Neoplasms / metabolism
-
Neoplasms / physiopathology
-
Pandemics
-
Pneumonia, Viral / drug therapy*
-
Pneumonia, Viral / genetics
-
Pneumonia, Viral / metabolism
-
Pneumonia, Viral / physiopathology
-
Protein Biosynthesis
-
SARS-CoV-2